3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Carcinoid Tumor
3
Neoplasms
2
Stomach Neoplasms
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Medulloblastoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hypertension
1
Interventions
3-Iodobenzylguanidine
3
olaparib
1
lutetium Lu 177 dotatate
1
entrectinib
1
entinostat
1
Pemetrexed
1
Paclitaxel
1
Dexamethasone
1
Calcium Dobesilate
1
Cabergoline
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
lutetium Lu 177 dotatate
×
Endocrine
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled